Press Release Summary:
Model MS-2040 provides measure-through motion and low perfusion oxygen saturation, pulse rate, and perfusion index measurements. Suited for use in portable medical devices, product is offered in double-stack version with dimensions of 1.8 x 1.15 x 0.46 in. and single-stack version with dimensions of 2.0 x 1.38 x 0.36 in. It is available as external board-in-cable solution, embedded within patient cable, to allow signal extraction pulse oximetry in handheld and patient-wearable applications.
Original Press Release:
Masimo Launches MS-2040, First Sub-45 mW Signal Extraction Pulse Oximetry Platform
New MS-2040 Circuit Board and External "Board-in-Cable" Promises to Usher in Breakthrough Pulse Oximetry Applications
IRVINE, Calif. - Masimo (NASDAQ: MASI) announced today the launch of its new sub-45 milliwatt technology platform--MS-2040. This platform utilizes nearly a third of the power and half of the physical board size of previously available Signal Extraction Pulse Oximetry solutions while providing the same proven unprecedented Measure-Through Motion and Low Perfusion oxygen saturation (SpO2), pulse rate, and perfusion index (PI) measurement capabilities of Masimo SET® pulse oximetry, in addition to Pleth Variability Index (PVI).
Using less than 45 milliwatts of power, Masimo MS-2040 boards are available in both a double-stack version with dimensions of 1.8" x 1.15" x 0.46" and single-stack version with dimensions of 2.0" x 1.38" x 0.36". The small size and reduced power consumption of Masimo MS-2040 boards enhance integration into next-generation portable medical devices that need to be smaller, lighter, and more mobile--consuming less than a third of the power without sacrificing accuracy during motion and low perfusion.
According to Masimo President of Worldwide OEM Business and Corporate Development, Rick Fishel, "Over the last 15 years, Masimo has worked diligently to continuously enhance pulse oximetry features and performance, including the development of cutting-edge circuitry innovations that have reduced the size of our boards by 90% and power consumption by 98%. Reducing the power usage profile and physical size of our circuit boards enables Masimo and our OEM partners to design smaller, lighter, and more portable monitoring devices with the high performance pulse oximetry capabilities clinicians need for successful utilization in these new sites and applications."
The MS-2040 circuit board is also available as an external "board-in-cable" solution. Embedded within a completely self-contained patient cable, the "board-in-cable" solution provides external Masimo SET pulse oximetry capabilities for existing devices that do not presently offer an integrated pulse oximetry solution. This affords medical equipment manufacturers a simpler way to add Masimo SET pulse oximetry as an external (oximeter outside) option and enables a wide range of reliable handheld and patient-wearable application possibilities.
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care--helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow® SET Pulse CO-Oximetry(TM) technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet(TM), a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow Acoustic Monitoring(TM), the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa(TM)). Masimo's rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. Masimo SET and Masimo rainbow SET technologies can be also found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57, Rad-8, Rad-5, Pulse CO-Oximetry, Pulse CO-Oximeter, MS-2040, and SEDLine are trademarks or registered trademarks of Masimo Corporation.
Web Site: www.masimo.com